The "World Association of Radiopharmaceutical and Molecular Therapy" (WARMTH) extends its activities throughout the world. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy, and of the relatively novel paradigm of ‘Theragnostics.’
WARMTH is a voluntary non-profit organization of individuals specifically associated for the purposes, and for using the means, to achieve the following research and educational objectives:
- Advance science and education of therapeutic nuclear medicine and radiopharmaceutical therapy including dosimetry, treatment evaluation, radiation physics, radiation biology and radiation protection for the benefit of public health and humanity.
- Work towards worldwide access to radionuclide therapy by harmonizing good practice.
- Educating nuclear medicine professionals in the use of radionuclide therapies and to facilitate research in this area.
The 14th ICRT will be held in Nanjing China from 22nd-25th August 2019 with pre-congress and opening on 21st August.
Abstracts submission extended to 22, June 2019. Awards to be given include: Life Achievement Award, Best Poster and Best Oral Presentation. A limited number of travel grants are available. Please click here in order to submit an application.
Dear Friends and Members of WARMTH,
The year 2019 is rolling on and we are looking forward to meeting many of you soon again at our ICRT-2019 to be held in Nanjing, China. We are fortunate to be part of an exciting team and to continue our service to WARMTH as President and President-Elect.
On this March 31st we celebrate with you on the first World “Theragnostics Day” celebrating the day in 1941 when the first radio iodine treatment was administered by Dr. Saul Hertz at Massachusetts General Hospital. The current issue of the WJNM reflects on this historic first treatment and the continuing innovations in the field of Theragnostics. WARMTH celebrates Theragnotstics Day with a “g” as an article by our colleagues in the EJNMMI points out "“theragnostics” is the better term with its emphasis on knowledge” Frangos, S. & Buscombe, J.R. Eur J Nucl Med Mol Imaging (2019) 46: 519. https://doi.org/10.1007/s00259-018-4204-z
WARMTH`s major meeting this year is the ICRT-2019. The Congress President of the ICRT-2019 is Feng Wang, Director of the Department of Nuclear Medicine at the Nanjing Medical University, has already started to build a unique platform for our meeting in Nanjing. The State-of-the-Art of radiopharmaceutical and molecular therapy and its clinical translation will extensively be discussed during the ICRT-2019 and will certainly promote Nuclear Therapy in China. Furthermore, the ICRT-2019 will not only promote the field of "Theragnostics" in China but will also promote the tremendous development of nuclear therapy all over the world! We heartily invite all of you once again to come to Nanjing, China, meet with WARMTH friends, contribute to the WARMTH ICRT-2019 and share also your experience at our exciting scientific as well as social programme. We are now opening the Abstract submission process with a tentative deadline of April 30, 2019, we sincerely hope that you will submit your scientific contribution. On our WARMTH website you will also find more information regarding the visa application for the congress. Please be informed that our annual 2019 members assembly will be held on August 24 and we look forward to meeting you all there!
WARMTH retrospective scientific studies are ongoing. We believe that one of WARMTH unique possibilities is to gather scientific data world-wide and speed up the process of theragnostic development. For both studies (177Lu-PSMA617 and Ga SSTR and FDG PET/CT in NETS) our under the lead of Hojat Ahmadzadehfar (Germany) and Margarida Rodrigues (Austria), retrospectively, you will find detailed information on our website (you must be a current member to access). Both studies are open for data contribution to all our distinguished WARMTH members.
Qaisar Siraj (Kuwait) has been appointed as the new Editor-in-chief of our World Journal of Nuclear Medicine as of 1st Jan 2019. The number of publications including original articles and case reports have increased, the reviewer’s database has been expanded and has been quadrupled to reduce the processing time and all accepted original articles are being planned to be printed online as ahead of print with unique DOI to allow authors timely credit for their original research work.
We look forward to seeing many of you at our various meetings during the rest of the year,
With warm(th)ly wishes,
|Irene Virgolini||Partha Choudhary|
|President, WARMTH||President-Elect, WARMTH|